Dear Biotechnology Peers,
Hope you’re staying safe and healthy during the coronavirus pandemic! Everyone is working hard on resisting this pandemic. COVID-19 is technology and vaccines issues tightly correlated to biotechnology. Technology is the most effective way to ease this pandemic. If you want to catch up with the latest information about the biotechnology industry, you better not miss out BIOHK2021 International Convention!
Biotechnology has emerged as one of the fastest growing sectors in Hong Kong and China in recent years. Recognizing its potential, the government has offered strong support through investment towards research and development and the building of infrastructure to foster close connections between industry, academia and investors. According to the Research Grants Council, between 2013/14 and 2017/18, 803 biotechnology-related projects in local universities were publicly-funded amounting to HK$1.2 billion, while outside of academia, through the Innovation and Technology Fund, over 460 biotechnology projects have been funded including those related to non-invasive prenatal diagnosis, robotics-assisted minimally invasive surgery and mini artificial heart.
Hong Kong, often considered the gateway to China due to its unique status as a special administrative region, offers a rich source of opportunities for overseas investors looking to capitalize the continued growth of the Greater Bay Area (GBA) – a scheme initiated by the Chinese government to link Hong Kong, Macau and 9 other cities along the Pearl River Estuary and form an international technology and innovation centre rivaling that of Silicon Valley. With its strong exposure and international integration, Hong Kong has become the go-to stepping stone for Chinese companies looking to expand abroad. New listing rules adopted by the Hong Kong Stock Exchange (HKEX) allowed pre-revenue biotech companies to be listed on the exchange. A first in Asia, it ensured more capital could flow freely towards a sector that’d been largely deprived in the region until recently. As of April 30, 2020, of the 16 pre-revenue biotech companies that completed their IPOs since the new listing rule, almost half have experienced a share price increase upwards of 60% from its issuance price. As such, owing to its geopolitical advantage, large number of world class universities and its position as the No. 1 biotech IPO market in Asia, Hong Kong has the potential to be at the epicentre of Asia’s biotech revolution and it is our hope that BIOHK2021 will help set this in motion.
COVID-19 has highlighted the importance of biotechnology. From rapid detection methods to vaccines, new drug developments and treatment equipment, biotechnology is the key to ending this pandemic, and it is our mission to showcase these advancements at BIOHK2021.
After close monitoring of the global risk assessment by the World Health Organization of the COVID-19 pandemic, the BIOHK2021 estimate that it is unlikely that the pandemic will be fully under control by the original scheduled time. There is a high probability that the pandemic will still have consequences in terms of public health in March 2021.
Bearing in mind not only the health and welfare of our participants and of the host community, but also the travel restrictions that are impacting our participants’ ability to attend the BIOHK2021, we have decided to postpone the BIOHK2021 to fall 2021. We hope you understand this is a necessary step to help keep each other safe in these unprecedented times.
We are aiming to bring you the world class biotech convention, our BIOHK2021 Presidents are from different fields of biotech for over 20 years, such as academia, the legal profession as well as the investment community. Such that, the BIOHK2021 will contain all the biotech elements to bring you a full range of biotech feast. We believe business opportunities are best made face to face, as such BIOHK2021 will offer one of the first large scale networking opportunities after the pandemic. We will work tirelessly for your support and will do everything in our power to ensure the event is an overwhelming success.
As a city with a rich history in industrial development and innovation, and one that is frequently coined “Asia’s World City”, there is no better place to bring biotech companies from East and West together other than here at BIOHK2021. Take charge and seize the many opportunities available and engage with global industry leaders at BIOHK2021.
With the successful development and popularization of the coronavirus vaccine, we believe that technology can take everyone out of the predicament. We look forward to seeing you in BIOHK2021.
- President, BIOHK2021
- Chairman, Hong Kong Biotechnology Organization
- Chairman, Guangdong-Hong Kong-Macao Greater Bay Area Biotechnology Alliance
- Professor, Peking University
- Co-president, BIOHK2021
- Chairman, The Bayhelix Group
- Partner, Jones Day Shanghai
- Co-president, BIOHK2021
- Founding Partner, Ausvic Capital Limited
- Life Honorary President, Hong Kong New Territories Regional Affairs Consultant Association
- Standing director, China Real Estate Developers and Investors Association
- General secretary, Guangdong-Hong Kong-Macao Greater Bay Area Finance Institute